European Journal Of Clinical Pharmacology

European Journal Of Clinical Pharmacology英文簡(jiǎn)介

The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed.

Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor.

Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves

-a compound that is interesting and new in some basic or fundamental way, or

-methods that are original in some basic sense, or

-a highly unexpected outcome, or

-conclusions that are scientifically novel in some basic or fundamental sense.

European Journal Of Clinical Pharmacology中文簡(jiǎn)介

《European Journal Of Clinical Pharmacology》是一本由SPRINGER HEIDELBERG出版商出版的專(zhuān)業(yè)醫(yī)學(xué)期刊，該刊創(chuàng)刊于1968年，刊期Monthly，該刊已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCI、SCIE收錄。在中科院最新升級(jí)版分區(qū)表中，該刊分區(qū)信息為大類(lèi)學(xué)科：醫(yī)學(xué) 3區(qū)，小類(lèi)學(xué)科：藥學(xué) 3區(qū)；在JCR（Journal Citation Reports）分區(qū)等級(jí)為Q3。該刊發(fā)文范圍涵蓋藥學(xué)等領(lǐng)域，旨在及時(shí)、準(zhǔn)確、全面地報(bào)道國(guó)內(nèi)外藥學(xué)工作者在該領(lǐng)域取得的最新研究成果、工作進(jìn)展及學(xué)術(shù)動(dòng)態(tài)、技術(shù)革新等，促進(jìn)學(xué)術(shù)交流，鼓勵(lì)學(xué)術(shù)創(chuàng)新。2021年影響因子為3.064，平均審稿速度一般,3-8周。

中科院分區(qū)最新升級(jí)版（當(dāng)前數(shù)據(jù)版本：2021年12月最新升級(jí)版）

大類(lèi)學(xué)科	分區(qū)	小類(lèi)學(xué)科	分區(qū)	Top期刊	綜述期刊
醫(yī)學(xué)	3區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué)	3區(qū)	否	否

中科院分區(qū)最新基礎(chǔ)版（當(dāng)前數(shù)據(jù)版本：2021年12月最新基礎(chǔ)版）

大類(lèi)學(xué)科	分區(qū)	小類(lèi)學(xué)科	分區(qū)	Top期刊	綜述期刊
醫(yī)學(xué)	3區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué)	3區(qū)	否	否

中科院JCR分區(qū)歷年趨勢(shì)圖

JCR分區(qū)（當(dāng)前數(shù)據(jù)版本：2021-2022年最新版）

JCR分區(qū)等級(jí)	JCR所屬學(xué)科	分區(qū)	影響因子
Q3	PHARMACOLOGY & PHARMACY	Q3	3.064

期刊指數(shù)

影響因子	h-index	Gold OA文章占比	研究類(lèi)文章占比	OA開(kāi)放訪(fǎng)問(wèn)	平均審稿速度
3.064	99	27.78%	73.51%	未開(kāi)放	一般,3-8周

IF值(影響因子)趨勢(shì)圖